Drug Profile
Research programme: atherothrombosis therapeutics - LG Chem
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Amidines; Antithrombotics; Dipeptides
- Mechanism of Action PAR-1 receptor agonists; Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in South Korea (PO)
- 20 Jul 2012 Preclinical development is ongoing in South Korea
- 27 Aug 2010 Preclinical development is ongoing in South Korea